India: Healthcare

In a recent ruling concerning trademark infringement in pharmaceuticals, a Division Bench of the Delhi High Court set aside a permanent injunction that restrained Intas Pharmaceuticals from selling its anti-cancer drug under the mark BEVATAS. The decision is significant for two reasons. First, it pushes back against the principle of “even the slightest possibility of confusion” which is standard in pharmaceutical cases due to the Supreme Court’s ruling in Cadila Healthcare (2001).

Can a pharmaceutical giant's two-decade-old brand name ‘A TO Z' command exclusive rights over those three terms in the multivitamin market? And what happens when a smaller competitor enters with a composite mark containing the same alphabetical endpoints, embedded within an entirely different word?

On 2 April 2026, the United States issued a Presidential Proclamation titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,”...